Mumbai, June 04: Wanbury Limited, a pharmaceutical company with a global API presence and domestic branded formulations portfolio, today announced its audited financial results for Q4 and FY26.
FY26 Performance Highlights:
|
Metric |
FY26 |
FY25 |
YoY Change |
|
Revenue from Operations |
₹650.3 Cr |
₹599.5 Cr |
+8.5% |
|
EBITDA* |
₹107.7 Cr |
₹79.8 Cr |
+34.9% |
|
EBITDA Margin |
16.5% |
13.2% |
+330 bps |
|
PAT |
₹66.1 Cr |
₹30.5 Cr |
+116.6% |
|
PAT Margin |
10.2% |
5.1% |
+509 bps |
|
EPS |
₹20.55 |
₹9.32 |
+122% |
|
*Includes Other Income |
Q4 FY26 Snapshot:
|
Metric |
Q4 FY26 |
QoQ Change |
YoY Change |
|
Revenue |
₹164.6 Cr |
+1.3% |
-4.3% |
|
EBITDA* |
₹30.1 Cr |
+11.9% |
-4.5% |
|
PAT |
₹21.7 Cr |
+37.7% |
+7.2% |
|
PAT Margin |
13.2% |
+150 bps YoY |
Financial Performance:
• FY26 PAT surges 117% YoY to ₹66.1 Cr, with PAT margin expanding 509 bps to 10.2%.
• EPS more than doubles from ₹9.32 to ₹20.55 in FY26, reflecting strong bottom-line growth.
• EBITDA grows 34.9% YoY to ₹107.7 Cr in FY26, driven by revenue growth, favourable product mix, better yields, procurement efficiencies, and process optimization.
• Q4 FY26 gross margin expands 887 bps YoY to 60.4%, despite revenue impact from West Asia crisis in March 2026.
Business & Operational Momentum:
• New Anaesthetic API launched from Tanuku facility after CAPEX completion. Commercial dispatches to Europe commenced February 2026.
• Pipeline strengthens with upcoming specialty APIs: Dextromethorphan HBr, Rivaroxaban, and Sitagliptin.
• Operational efficiency continues to improve as the company continued to invest in debottlenecking, process optimisation and manufacturing upgrades to improve capacity, operating leverage and scalability.
• Zero observations received in MFDS, Korea inspection conducted 7–9 April 2026. Previously, zero observations received in USFDA inspection at Patalganga facility, and zero observations in ANVISA Brazil inspection.
• ANVISA, Brazil approval secured for Sertraline Form II, deepening regulated market access.
• Formulations turnaround continues with improved performance and new launches across paediatric, nutraceutical, and specialty categories.
• SAP HANA S4 implemented to drive operational efficiencies across the organization.
Q4 FY26 Context:
Revenue from operations for Q4 FY26 stood at ₹164.6 crore vs ₹172.0 crore in Q4 FY25, impacted by West Asia crisis in late February disrupting API exports. Gross margin increased 11.1% YoY to ₹99.5 crore; EBITDA stood at ₹30.1 crore. PAT was ₹21.7 crore, reflecting a 7.2% YoY growth even after a one-time charge of ₹3.6 crore related to new labour codes. PAT margin improved by 150 bps to 13.2%.
Mr. Mohan Rayana, Director, Wanbury Limited, said: “FY26 was an important year for Wanbury. We strengthened business fundamentals through operational efficiencies, debottlenecking, balance sheet improvement, and expansion of our API and formulations portfolio. Improved plant utilisation, enhanced product yields, and procurement efficiencies supported better EBITDA margins.
The fourth quarter saw a revenue decline due to the West Asia crisis impacting API exports. Despite this, we continued growth on the back of new product launches in Q4. A key milestone was the launch of our new Anaesthetic API with commercial dispatches beginning February 2026. Clearing MFDS Korea inspection with zero observations validates our compliance systems. We will continue our API growth journey in FY27 with recent launches and a strong pipeline, while the formulations business will operate from a stronger footing supported by new launches and improved go-to-market strategy.”